Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study.
Shiratori S, Fukushima K, Onishi Y, Doki N, Goto T, Okada M, Nakamae H, Maeda Y, Kato K, Ishikawa T, Kondo T, Toyosaki M, Ikeda T, Uchida N, Maki A, Shimada F, Tajima T, Stefanelli T, Teshima T.
Shiratori S, et al. Among authors: maki a.
Int J Hematol. 2024 Oct 3. doi: 10.1007/s12185-024-03850-9. Online ahead of print.
Int J Hematol. 2024.
PMID: 39361234